Haemonetics (NYSE:HAE) Price Target Raised to $149.00

Haemonetics (NYSE:HAE) had its target price upped by Citigroup from $123.00 to $149.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s target price points to a potential upside of 24.30% from the company’s previous close.

Other research analysts have also issued reports about the company. BTIG Research upped their price objective on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Barrington Research lifted their target price on Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Friday. Robert W. Baird boosted their target price on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research report on Friday, August 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $121.00.

Haemonetics Stock Performance

Shares of NYSE:HAE traded down $4.24 during trading on Friday, reaching $119.87. 799,464 shares of the stock were exchanged, compared to its average volume of 811,712. Haemonetics has a 12 month low of $51.00 and a 12 month high of $132.00. The firm has a market cap of $5.45 billion, a PE ratio of 58.76, a PEG ratio of 2.55 and a beta of 0.63. The stock has a 50-day moving average price of $111.18 and a 200-day moving average price of $79.80. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, beating the consensus estimate of $1.29 by $0.06. The company had revenue of $357.76 million for the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.27 earnings per share. Research analysts expect that Haemonetics will post 5.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Fortitude Family Office LLC grew its position in Haemonetics by 104.5% during the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 139 shares during the last quarter. Root Financial Partners LLC acquired a new position in Haemonetics in the 3rd quarter worth about $40,000. Kelleher Financial Advisors bought a new position in Haemonetics in the second quarter valued at about $38,000. Northwestern Mutual Wealth Management Co. bought a new position in Haemonetics in the second quarter valued at about $44,000. Finally, Public Employees Retirement System of Ohio bought a new position in Haemonetics in the second quarter valued at about $54,000. 99.67% of the stock is owned by institutional investors.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings of $1.35 per share topped the $1.29 consensus, while revenue of $357.8 million exceeded estimates of $345.2 million and rose 9.4% year over year. Haemonetics reports Q2 results
• Positive Sentiment: The company raised its fiscal 2027 revenue and organic-growth outlook, forecasting organic growth of 6%–9%. It also expects to continue scaling the CSL Persona PLUS rollout through calendar 2027. FY 2027 growth outlook
• Positive Sentiment: Barrington Research raised its price target to $145 and maintained an “outperform” rating; BTIG Research raised its target to $142 and reiterated “buy.” These target increases signal continued analyst confidence after the results. Barrington Research target increase
• Neutral Sentiment: The earnings-call coverage highlighted growth-versus-margin trade-offs. That may temper enthusiasm if investors focus on the costs or profitability effects of scaling the business and product rollout. Earnings call highlights

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.